COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Costs Associated with Exit or Disposal ActivitiesItem 2.05. Costs Associated with Exit or Disposal Activities.
On June 21, 2017, the Compensation Committee of the Board of Directors of Coherus BioSciences, Inc. (the Company) approved, and management commenced and completed, a restructuring plan to reduce operating costs and better align its workforce with the needs of its business following the U.S. Food and Drug Administrations (FDA) June 12, 2017 issuance of a complete response letter for its Biologics License Application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, under the 351(k) pathway, in which the FDA stated that it cannot approve the Companys BLA for CHS-1701 in its present form and provided recommendations to the Company to address the issues raised in the letter.
Under this plan, the Company reduced its workforce by 51 employees (approximately 30%). Affected employees are eligible to receive severance payments, reimbursement of COBRA payments and outplacement services. Employees party to change of control and involuntary termination benefit agreements will continue to vest their stock options to the terms of their agreements. Certain senior executives received accelerated vesting of certain stock options and an extension to the post-termination exercise period for certain stock options. In each case, employee severance benefits are contingent upon an affected employees execution (and non-revocation) of a separation agreement, which includes a general release of claims against the Company. The Company expects that the workforce reduction will decrease its annual operating costs by approximately $10 million.
In connection with the restructuring, the Company estimates that it will incur aggregate restructuring charges of approximately $3.7 million, which will be recorded in the second quarter of 2017, related to one-time termination severance payments and other employee-related costs, including approximately $1.6 million of stock-based compensation expense related to the acceleration of stock options and the extension of post-termination stock option exercise periods. The majority of the cash payments related to the personnel-related restructuring charges will be paid during the third quarter of 2017, with the remainder to be paid during the fourth quarter of 2017. The charges that the Company expects to incur in connection with the workforce reduction is subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction.
This Item 2.05 contains forward-looking statements, including, but not limited to, statements related to the expected costs associated with termination benefits and the financial impact of the reduction in force. These forward-looking statements are based on the Companys current expectations and inherently involve significant risks and uncertainties. The Companys actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Companys workforce reduction costs may be greater than anticipated and the workforce reduction may have an adverse impact on the Companys development activities. A further description of the risks and uncertainties relating to the business of the Company is contained in the Companys Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2017, filed with the Securities and Exchange Commission (the SEC) on May 8, 2017, and the Companys subsequent current reports filed with the SEC. The Company undertakes no duty or obligation to update any forward-looking statements contained in this Item 2.05 as a result of new information, future events or changes in its expectations.
About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).